WO2001080844A2 - Method of treating dry eye disease with nicotinic acetylcholine receptor agonists - Google Patents
Method of treating dry eye disease with nicotinic acetylcholine receptor agonists Download PDFInfo
- Publication number
- WO2001080844A2 WO2001080844A2 PCT/US2001/013034 US0113034W WO0180844A2 WO 2001080844 A2 WO2001080844 A2 WO 2001080844A2 US 0113034 W US0113034 W US 0113034W WO 0180844 A2 WO0180844 A2 WO 0180844A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- analogs
- acetylcholine receptor
- nicotinic acetylcholine
- receptor agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60101201T DE60101201D1 (en) | 2000-04-21 | 2001-04-19 | USE OF NICOTINERGEN ACETYLCHOLIN RECEPTOR AGONISTS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF KERATOCONJUCTIVITIS SICCA |
EP01927298A EP1214062B1 (en) | 2000-04-21 | 2001-04-19 | Use of nicotinic acetylcholine receptor agonists for the preparation of a medicament for the treatment of dry eye disease |
JP2001577943A JP2003531168A (en) | 2000-04-21 | 2001-04-19 | Method for treating dry eye disease with nicotine acetylcholine receptor agonist |
AU2001253765A AU2001253765A1 (en) | 2000-04-21 | 2001-04-19 | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
AT01927298T ATE253912T1 (en) | 2000-04-21 | 2001-04-19 | USE OF NICOTINERGIC ACETYLCHOLINE RECEPTOR AGONISTS FOR PRODUCING A MEDICATION FOR THE TREATMENT OF KERATOCONJUCTIVITIS SICCA |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/557,059 | 2000-04-21 | ||
US09/557,059 US6277855B1 (en) | 2000-04-21 | 2000-04-21 | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001080844A2 true WO2001080844A2 (en) | 2001-11-01 |
WO2001080844A3 WO2001080844A3 (en) | 2002-03-28 |
Family
ID=24223897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/013034 WO2001080844A2 (en) | 2000-04-21 | 2001-04-19 | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
Country Status (8)
Country | Link |
---|---|
US (1) | US6277855B1 (en) |
EP (1) | EP1214062B1 (en) |
JP (1) | JP2003531168A (en) |
AR (1) | AR028026A1 (en) |
AT (1) | ATE253912T1 (en) |
AU (1) | AU2001253765A1 (en) |
DE (1) | DE60101201D1 (en) |
WO (1) | WO2001080844A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US7326683B2 (en) | 2004-05-06 | 2008-02-05 | Molichem Medicines, Inc. | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions |
US7479481B2 (en) | 2004-05-06 | 2009-01-20 | Molichem Medicines, Inc. | Treatment of ocular diseases and disorders using lantibiotic compositions |
WO2011151807A1 (en) | 2010-06-04 | 2011-12-08 | Pfizer Vaccines Llc | Conjugates for the prevention or treatment of nicotine addiction |
US8445684B2 (en) | 2008-10-14 | 2013-05-21 | PsycoGenics Inc. | Nicotinic acetylcholine receptor ligands and the uses thereof |
US8557819B2 (en) | 2005-08-18 | 2013-10-15 | Sanofi | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics |
WO2015173685A1 (en) | 2014-05-16 | 2015-11-19 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
WO2016073667A1 (en) * | 2014-11-05 | 2016-05-12 | Tissuetech, Inc. | Compositions and method for promoting nerve growth and regeneration |
US9682160B2 (en) | 2011-08-26 | 2017-06-20 | Tissuetech, Inc. | Methods of sterilizing fetal support tissues |
US9682044B2 (en) | 2011-06-10 | 2017-06-20 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
US9724370B2 (en) | 2005-09-27 | 2017-08-08 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
US9750772B2 (en) | 2005-09-27 | 2017-09-05 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
US10456396B2 (en) | 2014-10-20 | 2019-10-29 | Oyster Point Pharma, Inc. | Dry eye treatments |
US10709707B2 (en) | 2016-04-07 | 2020-07-14 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596725B2 (en) * | 1997-02-10 | 2003-07-22 | Inspire Pharmaceuticals, Inc. | Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema |
US7223744B2 (en) * | 1997-02-10 | 2007-05-29 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof |
US6818629B2 (en) | 1997-02-10 | 2004-11-16 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate |
US7078391B2 (en) * | 1997-02-10 | 2006-07-18 | Inspire Pharmaceuticals, Inc. | Method of treating edematous retinal disorders |
US6455554B1 (en) * | 1999-06-07 | 2002-09-24 | Targacept, Inc. | Oxopyridinyl pharmaceutical compositions and methods for use |
US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
WO2001068104A1 (en) * | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
US6596740B2 (en) * | 2000-10-24 | 2003-07-22 | Richard L. Jones | Nicotine mucosal spray |
GB2381750A (en) * | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
US6852741B2 (en) | 2001-12-31 | 2005-02-08 | University Of Florida | Compositions and methods for treatment of neurological disorders |
US6659985B2 (en) | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
US7069084B2 (en) * | 2002-06-14 | 2006-06-27 | Seefit Incorporated | Method and apparatus for preventing and treating eyelid problems |
EP1539152A4 (en) * | 2002-08-02 | 2006-10-18 | Nutraceutical Dev Corp | Development of muscle mass in a mammal |
US7179481B2 (en) * | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
US20060035811A1 (en) * | 2002-10-18 | 2006-02-16 | Luis Molina | Methods of treating dry eye disease with lantibiotics |
JP4667041B2 (en) * | 2002-11-08 | 2011-04-06 | ザ マクレーン ホスピタル コーポレーション | Compounds for the treatment of tobacco dependence and withdrawal symptoms |
US7098189B2 (en) * | 2002-12-16 | 2006-08-29 | Kimberly-Clark Worldwide, Inc. | Wound and skin care compositions |
US7056889B2 (en) | 2002-12-16 | 2006-06-06 | Kimberly-Clark, Worldwide, Inc. | Compounds that bind P2Y2 or P2Y1 receptors |
RU2366428C2 (en) * | 2002-12-20 | 2009-09-10 | Дзе Маклин Хоспитал Корпорейшн | Compounds used for sleep/wakefulness cycle normalisation |
US20060036220A1 (en) * | 2003-01-22 | 2006-02-16 | Kohji Kawahara | Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye |
US20050013806A1 (en) * | 2003-04-04 | 2005-01-20 | Chang Min S. | Use of contact lens for corneal cell transplant |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US9216106B2 (en) * | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
AU2004317087A1 (en) * | 2003-10-08 | 2005-09-22 | The Mclean Hospital Corporation | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
US20050113449A1 (en) * | 2003-10-08 | 2005-05-26 | Renshaw Perry F. | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
AU2003296968A1 (en) * | 2003-12-12 | 2005-07-14 | Richard W. Yee | Method and apparatus for preventing and treating eyelid problems |
US20060270592A1 (en) * | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
PL1754491T3 (en) * | 2004-05-21 | 2010-08-31 | Senju Pharma Co | Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
CA2529613C (en) | 2004-06-03 | 2013-10-01 | Senju Pharmaceutical Co., Ltd. | Agent for repairing corneal sensitivity containing amide compound |
US7737128B2 (en) * | 2004-06-10 | 2010-06-15 | The Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
WO2005123097A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder |
US7485666B2 (en) * | 2004-06-17 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
EP1784199A4 (en) * | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
WO2006082588A2 (en) * | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
CN101232882A (en) * | 2005-07-26 | 2008-07-30 | 千寿制药株式会社 | Percutaneously absorbable ophthalmic preparation |
US20070231360A1 (en) * | 2006-03-28 | 2007-10-04 | Minu, L.L.C. | Neural conduit agent dissemination |
US20070237797A1 (en) * | 2006-03-28 | 2007-10-11 | Gholam A. Peyman | Neural Conduit Agent Dissemination |
US20070297991A1 (en) * | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Neural conduit agent dissemination for smoking cessation and other applications |
US20080107713A1 (en) * | 2006-11-08 | 2008-05-08 | Orilla Werhner C | Contact lens as a sustained drug delivery implant |
US20080317819A1 (en) * | 2007-06-21 | 2008-12-25 | Orilla Werhner C | Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas |
US20090004244A1 (en) * | 2007-06-27 | 2009-01-01 | Orilla Werhner C | Iris design as a drug depot for zonal drug delivery by contact lens |
US20090004245A1 (en) * | 2007-06-28 | 2009-01-01 | Orilla Werhner C | Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens |
DE102007055046A1 (en) * | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | infusion |
GB0724558D0 (en) * | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
WO2009139470A1 (en) * | 2008-05-16 | 2009-11-19 | 学校法人聖マリアンナ医科大学 | Pharmaceutical composition for treatment of fibromyalgia |
US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
ES2606546T3 (en) * | 2009-02-11 | 2017-03-24 | Heglund, A.S. | Compound intended for oral absorption of nicotine with the aim of quitting smoking |
EP2640461B1 (en) | 2010-11-16 | 2019-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Systems for treatment of dry eye |
US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
JP6527305B2 (en) * | 2011-01-10 | 2019-06-05 | インヴィオン, インコーポレイテッド | Use of beta-adrenergic inverse agonists for smoking cessation |
US9132193B2 (en) | 2012-11-05 | 2015-09-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of Slurp1 as an imunomodulatory molecule in the ocular surface |
RU2510701C1 (en) * | 2012-12-19 | 2014-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) | Method of treating blepharoconjunctival form of dry eye syndrome |
US9265956B2 (en) | 2013-03-08 | 2016-02-23 | Oculeve, Inc. | Devices and methods for treating dry eye in animals |
US9717627B2 (en) | 2013-03-12 | 2017-08-01 | Oculeve, Inc. | Implant delivery devices, systems, and methods |
CN105307718B (en) | 2013-04-19 | 2018-05-11 | 奥库利维公司 | Nose stimulating apparatus and method |
EP3689338A1 (en) | 2014-02-25 | 2020-08-05 | Oculeve, Inc. | Polymer formulations for nasolacrimal stimulation |
DK3171928T3 (en) | 2014-07-25 | 2020-05-18 | Oculeve Inc | STIMULATION PATTERNS FOR TREATMENT OF DRY EYES |
WO2016065213A1 (en) | 2014-10-22 | 2016-04-28 | Oculeve, Inc. | Implantable nasal stimulator systems and methods |
AU2015335776B2 (en) | 2014-10-22 | 2020-09-03 | Oculeve, Inc. | Stimulation devices and methods for treating dry eye |
US9764150B2 (en) | 2014-10-22 | 2017-09-19 | Oculeve, Inc. | Contact lens for increasing tear production |
JP7030516B2 (en) | 2014-12-31 | 2022-03-07 | マイクロオプティクス インコーポレイテッド | Glaucoma treatment equipment and methods |
JP6785796B2 (en) * | 2015-05-21 | 2020-11-18 | オフタルミ モナコOphtalmis Monaco | Combination of lipoic acid and taurine as osmoprotectant |
JP2017052723A (en) * | 2015-09-10 | 2017-03-16 | 株式会社Lttバイオファーマ | Dry eye improver |
JP6892693B2 (en) | 2015-09-30 | 2021-06-23 | マイクロオプティクス インコーポレイテッド | Dry eye treatment equipment and methods |
US10426958B2 (en) | 2015-12-04 | 2019-10-01 | Oculeve, Inc. | Intranasal stimulation for enhanced release of ocular mucins and other tear proteins |
US10252048B2 (en) | 2016-02-19 | 2019-04-09 | Oculeve, Inc. | Nasal stimulation for rhinitis, nasal congestion, and ocular allergies |
MX2018012439A (en) | 2016-04-12 | 2019-02-21 | Solis Herrera Arturo | Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists. |
CA3022683A1 (en) | 2016-05-02 | 2017-11-09 | Oculeve, Inc. | Intranasal stimulation for treatment of meibomian gland disease and blepharitis |
JP2020500609A (en) | 2016-12-02 | 2020-01-16 | オキュリーブ, インコーポレイテッド | Apparatus and method for dry eye prediction and treatment recommendations |
TW202019424A (en) * | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | Methods of treating ocular conditions |
WO2023279162A1 (en) * | 2021-07-07 | 2023-01-12 | University Of Canberra | Methods of treatment and inhibition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998000119A2 (en) * | 1996-07-02 | 1998-01-08 | Boehringer Ingelheim Pharma Kg | Applications of active substances affecting the functions of non neuronal acetylcholine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
US4868154A (en) | 1986-02-19 | 1989-09-19 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with melanocyte stimulating hormones |
JP3034953B2 (en) | 1992-08-31 | 2000-04-17 | ユニバーシティー オブ フロリダ リサーチ ファンデーション,インコーポレーテッド | Anabaseine derivatives useful for the treatment of degenerative diseases of the nervous system |
US5817679A (en) | 1993-04-01 | 1998-10-06 | University Of Virginia | 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands |
US5723477A (en) | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
US5696166A (en) * | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
US5900407A (en) | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
US5830904A (en) | 1997-02-05 | 1998-11-03 | University Of Kentucky Research Foundation | Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders |
US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
-
2000
- 2000-04-21 US US09/557,059 patent/US6277855B1/en not_active Expired - Fee Related
-
2001
- 2001-04-19 WO PCT/US2001/013034 patent/WO2001080844A2/en active IP Right Grant
- 2001-04-19 DE DE60101201T patent/DE60101201D1/en not_active Expired - Lifetime
- 2001-04-19 JP JP2001577943A patent/JP2003531168A/en active Pending
- 2001-04-19 AU AU2001253765A patent/AU2001253765A1/en not_active Abandoned
- 2001-04-19 AT AT01927298T patent/ATE253912T1/en not_active IP Right Cessation
- 2001-04-19 EP EP01927298A patent/EP1214062B1/en not_active Expired - Lifetime
- 2001-04-23 AR ARP010101875A patent/AR028026A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998000119A2 (en) * | 1996-07-02 | 1998-01-08 | Boehringer Ingelheim Pharma Kg | Applications of active substances affecting the functions of non neuronal acetylcholine |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US7326683B2 (en) | 2004-05-06 | 2008-02-05 | Molichem Medicines, Inc. | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions |
US7479481B2 (en) | 2004-05-06 | 2009-01-20 | Molichem Medicines, Inc. | Treatment of ocular diseases and disorders using lantibiotic compositions |
US8557819B2 (en) | 2005-08-18 | 2013-10-15 | Sanofi | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics |
US10632155B2 (en) | 2005-09-27 | 2020-04-28 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
US9750772B2 (en) | 2005-09-27 | 2017-09-05 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
US10272119B2 (en) | 2005-09-27 | 2019-04-30 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
US9956252B2 (en) | 2005-09-27 | 2018-05-01 | Tissuetech, Inc. | Purified amniotic membrane compositions and methods of use |
US9724370B2 (en) | 2005-09-27 | 2017-08-08 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
US9750771B2 (en) | 2005-09-27 | 2017-09-05 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and anti-inflammation methods |
US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
US8445684B2 (en) | 2008-10-14 | 2013-05-21 | PsycoGenics Inc. | Nicotinic acetylcholine receptor ligands and the uses thereof |
WO2011151807A1 (en) | 2010-06-04 | 2011-12-08 | Pfizer Vaccines Llc | Conjugates for the prevention or treatment of nicotine addiction |
US10426731B2 (en) | 2011-06-10 | 2019-10-01 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
US9682044B2 (en) | 2011-06-10 | 2017-06-20 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
US9682160B2 (en) | 2011-08-26 | 2017-06-20 | Tissuetech, Inc. | Methods of sterilizing fetal support tissues |
US9931423B2 (en) | 2011-08-26 | 2018-04-03 | Tissuetech, Inc. | Methods of sterilizing fetal support tissues |
US9475793B2 (en) | 2014-05-16 | 2016-10-25 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
US9303013B2 (en) | 2014-05-16 | 2016-04-05 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
WO2015173685A1 (en) | 2014-05-16 | 2015-11-19 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
US10456396B2 (en) | 2014-10-20 | 2019-10-29 | Oyster Point Pharma, Inc. | Dry eye treatments |
US11224598B2 (en) | 2014-10-20 | 2022-01-18 | Oyster Point Pharma, Inc. | Methods of increasing lacrimal proteins |
US11903943B2 (en) | 2014-10-20 | 2024-02-20 | Oyster Point Pharma, Inc. | Compositions and use of varenicline for treating dry eye |
US11903942B2 (en) | 2014-10-20 | 2024-02-20 | Oyster Point Pharma, Inc. | Compositions and use of varenicline for treating dry eye |
US11903941B2 (en) | 2014-10-20 | 2024-02-20 | Oyster Point Pharma, Inc. | Compositions and use of varenicline for treating dry eye |
US11911380B2 (en) | 2014-10-20 | 2024-02-27 | Oyster Point Pharma, Inc. | Compositions and use of varenicline for treating dry eye |
WO2016073667A1 (en) * | 2014-11-05 | 2016-05-12 | Tissuetech, Inc. | Compositions and method for promoting nerve growth and regeneration |
US10709707B2 (en) | 2016-04-07 | 2020-07-14 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
Also Published As
Publication number | Publication date |
---|---|
AU2001253765A1 (en) | 2001-11-07 |
AR028026A1 (en) | 2003-04-23 |
EP1214062B1 (en) | 2003-11-12 |
EP1214062A2 (en) | 2002-06-19 |
ATE253912T1 (en) | 2003-11-15 |
JP2003531168A (en) | 2003-10-21 |
US6277855B1 (en) | 2001-08-21 |
DE60101201D1 (en) | 2003-12-18 |
WO2001080844A3 (en) | 2002-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1214062B1 (en) | Use of nicotinic acetylcholine receptor agonists for the preparation of a medicament for the treatment of dry eye disease | |
US7247623B2 (en) | Method of treating dry eye disease with non-drying antihistamines | |
US20090325959A1 (en) | Method for treating ophthalmic diseases using rho kinase inhibitor compounds | |
WO1997002823A1 (en) | Use of polyamine antagonists for the treatment of glaucoma | |
JP2007217437A (en) | Method for reducing intraocular pressure in mammal by administration of potassium channel blocker | |
US6730707B2 (en) | Method for reducing intraocular pressure using indole derivatives | |
US6448276B1 (en) | Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists | |
WO2002009702A2 (en) | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure | |
US20030069272A1 (en) | Method of enhancing joint lubrication with nicotinic acetylcholine receptor agonists | |
WO2001017527A1 (en) | Preventive and therapeutic agents for eye diseases | |
US20100190734A1 (en) | Method of treating dry eye disease with azithromycin | |
US20050009902A1 (en) | Remedies for pruritus | |
EP0871446B1 (en) | Use of eliprodil for the manufacture of a medicament for the treatment of ischemic disorders of the retina or the optic nerve | |
WO2002040028A1 (en) | Antibacterial gel eye drops | |
EP2072047A1 (en) | Therapeutic agent for opthalmic disease | |
KR100585299B1 (en) | Optic papillary circulation improving agents | |
AU716577B2 (en) | Use of polyamine antagonists for the treatment of glaucoma | |
KR20030087029A (en) | Remedies for retina and choroid diseases containing steroids as the active ingredient | |
JP2000515548A (en) | How to treat nicotine withdrawal symptoms | |
JP2002356431A (en) | Therapeutic agent for retinochoroidal disease containing steroid as active ingredient | |
WO2007066678A1 (en) | Therapeutic agent for corneal/conjuctival disease | |
JPH11508879A (en) | Use of polyamine antagonists for the treatment of glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001927298 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 577943 Kind code of ref document: A Format of ref document f/p: F |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2001927298 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001927298 Country of ref document: EP |